The availability of market data is no longer a constraint for most financial institutions. The real challenge lies in identifying data that is accurate, representative, and fit for purpose—particularly in over‑the‑counter (OTC) markets, where transparency is limited and liquidity is fragmented.
1. Data Credibility and Independence
One of the most important considerations is whether the data is independent and free from conflicts of interest. In OTC markets, where pricing is often negotiated bilaterally, data derived from actual market activity provides a more reliable reference point than model‑only or consensus‑based estimates.
Vendors that source pricing from real interdealer trading activity are generally better positioned to reflect genuine market conditions. Independent data also supports fair valuation, execution analysis, and regulatory reporting, helping firms demonstrate transparency and consistency in their decision‑making.
2. Depth and Breadth of Asset Class Coverage
OTC markets span a wide range of asset classes, including cash instruments and derivatives across rates, credit, FX, commodities, and energy markets. A suitable vendor should offer not only broad asset class coverage, but also sufficient depth within each class—covering multiple instruments, currencies, tenors, and structures.
This level of coverage is particularly important for firms managing complex or multi‑asset portfolios, where gaps in data can lead to inconsistent valuation or risk assessment.
3. Representativeness of Market Liquidity
The usefulness of OTC market data depends heavily on how well it reflects underlying liquidity. Vendors with access to a meaningful share of market activity are typically better able to calibrate pricing models and benchmarks that align with real trading conditions.
Understanding the provenance of the data—how it is collected, how frequently it updates, and how it reflects active markets—can help firms assess whether the data is suitable for their use cases.
4. Global Coverage
Many OTC instruments are traded across regions and currencies, often with varying liquidity profiles. Firms operating internationally should consider whether a data provider offers truly global coverage or is limited to specific regions or major economies.
Global OTC market data can be particularly valuable for cross‑border trading, portfolio aggregation, and risk management, where regional blind spots may otherwise distort analysis.
5. Data Quality Controls and Governance
Strong data governance is essential in OTC markets. Firms should look for vendors with clear processes around data validation, quality checks, and exception handling. This includes transparency around how outliers are treated, how missing data is addressed, and how benchmarks are constructed.
Robust governance frameworks help ensure consistency over time and increase confidence in downstream analytics.
6. Flexible Delivery and Integration
OTC market data is most effective when it can be easily integrated into existing workflows. Vendors should support multiple delivery methods to accommodate different technology stacks and operational requirements, such as:
- Real‑time data streaming
- Scheduled file delivery
- Direct integration into cloud environments
- Distribution via established third‑party platforms
Flexibility in delivery allows firms to use the same data across front‑office trading, middle‑office risk, and back‑office reporting functions.
7. Support for Multiple Use Cases
Finally, firms should assess whether the data can support a range of use cases across the trade lifecycle. High‑quality OTC data should be usable for:
- Pre‑trade research and price discovery
- Valuation and portfolio monitoring
- Risk management and stress testing
- Post‑trade analysis and regulatory reporting
Structured, enriched data that can be applied consistently across these functions is typically more valuable than raw price feeds alone.
Watch the video below— and see why high quality OTC market data is a genuine differentiator for traders, quants, and risk teams.
In summary, selecting an OTC market data vendor requires careful consideration of data independence, market representativeness, asset class coverage, governance, and delivery flexibility. In markets where transparency is limited, the quality and provenance of data are often more important than volume alone
OTC markets data from Parameta Solutions
High‑quality OTC market data is defined by how accurately it reflects real trading conditions, and Parameta’s data is grounded in the wholesale interdealer activity that underpins global OTC markets. By drawing on pricing derived from actual market transactions, Parameta offers:
- High‑quality OTC market data, indices and analytics across interest rate swaps and options, money markets, FX, and energy and commodities
- Data from the world’s largest inter-dealer broker, TP ICAP and other leading liquidity venues
- Coverage across 200+ asset classes
- Accurate real world data sets
- Independent and unconflicted data
- Seamless and secure data delivery direct, via cloud or third party distributor
- Strong data governance
For more information on our derivative data solutions, please contact us to discuss your requirements or see a data sample.
Disclaimer
© 2026 ICAP Information Services Limited (“IISL”). This communication is provided by ICAP Information Services Limited or a member of its group (“Parameta”) and all information contained in or attached hereto (the “Information”) is for information purposes only and is confidential. Access to the Information by anyone other than the intended recipient is unauthorised without Parameta’s prior written approval. The Information may not be not used or disclosed for any purpose without Parameta’s prior written approval, including without limitation, storing, copying, distributing, licensing, selling or displaying the Information, using the Information in an application or to create derived data of any kind, co-mingling the Information with any other data or using the data for any unlawful purpose of for any purpose that would cause it to become a benchmark under any law, regulation or guidance. The Information is not, and should not be construed as, a live price, an offer, bid, recommendation or solicitation in relation to any financial instrument or investment or to participate in any particular trading strategy or constituting financial or investment advice or a financial promotion. The Information does not constitute a public offer under any applicable legislation or an offer to sell or a solicitation of an offer to buy any securities. The Information is not to be relied upon for any purpose whatsoever and is provided “as is” without warranty of any kind, either expressly or by implication, including without limitation as to completeness, timeliness, accuracy, continuity, merchantability or fitness for any particular purpose. All representations and warranties are expressly disclaimed, to the fullest extent possible under applicable law. In no circumstances will Parameta be liable for any indirect or direct loss, or consequential loss or damages including without limitation, loss of business or profits arising from the use of, any inability to use, or any inaccuracy in the Information. Parameta may suspend, withdraw or modify or change the terms of the provision of the Information at any time in its sole discretion, without notice. All rights, including without limitation intellectual property rights, in and to the Information are, and shall remain, the property of IISL or its licensors. Use of, access to or delivery of Parameta’s products and/or services requires a prior written licence from Parameta or its relevant affiliates. The terms of this disclaimer are governed by the laws of England and Wales.
